SEC Form 4 · accession 0001390478-16-000111
SELLAS Life Sciences Group, Inc. · SLS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ryan Dunlap
Officer — Former Chief Financial Officer
Period of report
Jun 1, 2016
Accepted (ET)
Jun 7, 2016 · 6:36 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001390478
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jun 1, 2016 | M | 31,250 | $1.75 | A | 49,952 | D | |
| Common Stock | Jun 1, 2016 | M | 65,625 | $1.85 | A | 115,577 | D | |
| Common Stock | Jun 1, 2016 | M | 30,000 | $1.71 | A | 145,577 | D | |
| Common StockF1 | Jun 1, 2016 | S | 126,875 | $2.18 | D | 18,702 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock OptionF2,F3 | $1.75 | Jun 1, 2016 | M | 31,250 | D | — | — | Common Stock | 31,250 | 95,625 | D |
| Stock OptionF4,F3 | $1.85 | Jun 1, 2016 | M | 65,625 | D | — | — | Common Stock | 65,625 | 30,000 | D |
| Stock OptionF5,F3 | $1.71 | Jun 1, 2016 | M | 30,000 | D | — | — | Common Stock | 30,000 | 0 | D |
Explanation of responses
- F1The Price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $2.16 to $2.22 per share. The reporting person undertakes the provide to the Issuer, any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. The trades settled on June 6, 2016.
- F2The option vests on a quarterly basis over four years, commencing on the last day of the quarter after the date of grant (1/15/15).
- F3This stock option was subject to cancellation on June 29, 2016, which was 90 days after the Reporting person's consulting agreement ended with the Issuer.
- F4The option vests on a quarterly basis over four years, commencing on the last day of the quarter after the date of grant (7/9/12).
- F5The option vests on a quarterly basis over four years, commencing on the last day of the quarter after the date of grant (1/29/13).